Drug Price Lists and Pricing Policies

The New Brunswick Drug Plans set a maximum price that will be reimbursed for drugs. The New Brunswick Drug Plans include the New Brunswick Prescription Drug Program (NBPDP), New Brunswick Drug Plan (Plan D), Extra-Mural Program (Plan W), and Public Health (Plan P).

This maximum price is applied during claims adjudication as outlined below:
 

The maximum amount that the New Brunswick Drug Plans will reimburse for one unit of a drug product in this category is the Manufacturer List Price (MLP) specified in the MLP List.

MLP List: PDF | XLS
 

The maximum amount that the New Brunswick Drug Plans will reimburse for one unit of a drug product in this category (e.g. pharmaceutical equivalent, pharmaceutical alternative, interchangeable) is the Maximum Allowable Price (MAP) specified in the MAP List.

• MAP prices that are highlighted in grey have been increased due to shortages of products in the category.
• Product names that are highlighted in grey indicate that the manufacturer has not confirmed the MAP price for all package sizes of the product.

MAP List: PDF | XLS

The MAP for each category is determined by calculating a percentage of the price of the reference brand name drug.

If there is no drug, other than the original product, with a Notice of Compliance on June 1, 2013:

Solid Oral Dosage Form: 25% of the MLP of the original product as of the date a Notice of Compliance is issued for the first product in a MAP category, other than the original product

Non-Solid Oral Dosage Form: 35% of the MLP of the original product as of the date a Notice of Compliance is issued for the first product in a MAP category, other than the original product

If there is another drug, other than the original product, with a Notice of Compliance on June 1, 2013:

Solid Oral Dosage Form: 25% of the original product price as of January 1, 2010

Non-Solid Oral Dosage Form: 35% of the original product price as of January 1, 2010

pan-Canadian Competitive Value Price Initiative for Generic Drugs

Provinces and territories work together to lower generic drug prices through the Council of the Federation’s pan-Canadian Competitive Value Price Initiative for Generic Drugs.  Under this initiative, the prices of certain generic drugs are set at 10 or 18% of the brand name drug price.

Exceptions

The MAP for a category may be varied if the proposed price is not higher than the price in another Canadian jurisdiction and one or more of the following conditions exists: 

• the manufacturer provides documentation indicating that a different unit price should be established;
• the manufacturer’s list price for the original product has changed;
• the original product is no longer marketed in Canada or another product with similar ingredients, strength and form has received a notice of compliance;
• it is justified having regard to market conditions; or
• it is justified in the public interest having regard to the safety of members of the Plan, access to the drug or costs to the Plan.
   

For extemporaneous preparations (compounds), the maximum amount that the New Brunswick Drug Plans will reimburse for one unit (e.g. tablet, capsule, milliliter, gram, etc.) is the actual acquisition cost.  Actual acquisition cost means the unit price of a drug to a participating provider, based on reasonable and customary purchasing practices, which is calculated by deducting from the total amount paid or payable to purchase the drug, (excluding franchise fees and shipping charges), the value of any price reduction.  

Payments made for actual acquisition costs that do not comply with this policy are subject to audit and recovery.